New ASH Summit Encourages Practical, Elevated Dialogue on Emerging Immunotherapies
The ASH Summit on Emerging Immunotherapies for Hematologic Diseases program co-chairs Drs. Catherine Bollard, Rodrigo Calado, Sergio Giralt, and Jeffrey Miller share their
Novel Insights From Comprehensive Genomic Profiling of T Cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that helps expand understanding of T-cell acute lymphoblastic leukemia biology.
Drs. George and Conant review a study that shows that in patients with unexplained cytopenias, the detection of somatic mutations can stratify patients into being at low or high risk for developing myeloid malignancies. CHIP has clinical impact beyond increased risk for developing hematopoietic neoplasms and may have further implications in nonhematologic areas.
Dr. George and Dr. Marlar discuss the use of IgG-specific ELISA assays to more accurately detect HIT antibodies.
Dr. Davion and Dr. George take a look at a trial that studies the addition of eltrombopag to standard therapy to improve rates of hematologic response in patients with severe aplastic anemia.
Dr. George discusses the use of multiparametric flow cytometry in patients with amyloid light-chain amyloidosis, at diagnosis and at the end of treatment.
Drs. Sojitra, Arber, and George cover the 2017 joint guidelines from ASH and the College of American Pathologists on testing for the initial workup of acute leukemia.
Dr. George and Dr. Allen discuss advances in the field of myeloproliferative neoplasms that have come about in 2016.
Dr. George and Dr. Yan look at a comprehensive genetic study of relapsed childhood B-ALL, which provides compelling evidence that refining risk classification by integrating genetic and clinical risk factors improves patient stratification and outcome.
Dr. George and Dr. Gullapalli provide a thorough synopsis of the history of Theranos, a medical and technological innovations laboratory company founded by Elizabeth Holmes.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
Dr. George and Dr. Chabot-Richards discuss a study that shows the different roles of NPM1 mutation in risk stratification and MRD monitoring in AML.
January-February 2018Volume 15, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology